Skip to main content
SpringerLink
Log in

Biliary Tract Infections

A Guide to Drug Treatment

  • Disease Management
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Initial therapy of acute cholecystitis and cholangitis is directed towards general support of the patient, including fluid and electrolyte replacement, correction of metabolic imbalances and antibacterial therapy.

Factors affecting the efficacy of antibacterial therapy include the activity of the agent against the common biliary tract pathogens and pharmacokinetic properties such as tissue distribution and the ratio of concentration in both bile and serum to the minimum inhibitory concentration for the expected micro-organism. Antimicrobial therapy is usually empirical. Initial therapy should cover the Enterobacteriaceae, in particular Escherichia coli. Activity against enterococci is not required since their pathogenicity in biliary tract infections remains unclear. Coverage of anaerobes, in particular Bacteroides spp., is warranted in patients with previous bile duct-bowel anastomosis, in the elderly and in patients in serious clinical condition.

In patients with acute cholecystitis or cholangitis of moderate clinical severity, monotherapy with a ureidopenicillin — mezlocillin or piperacillin — is at least as effective as the combination of ampicillin plus aminoglycoside. In severely ill patients with septicaemia, an antibacterial combination is preferable. Therapy with aminoglycosides, mostly for Pseudomonas aeruginosa- related infections, should not exceed a few days because the risk of nephrotoxicity seems to be increased during cholestasis.

Relief of biliary obstruction is mandatory, even if there is clinical improvement with conservative therapy, because cholangitis is most likely to recur with continued obstruction. Emergency invasive therapy is reserved for patients who fail to show a clinical response to antibacterial therapy within the first 36 to 48 hours or for those who deteriorate after an initial clinical improvement. Immediate surgery is indicated for gangrenous cholecystitis and perforation with peritonitis. Long-term administration of antibacterials is required for recurrent cholangitis, as seen in bile duct-bowel anastomosis. Oral cotrimoxazole (trimethoprim/sulfamethoxazole) is the preferred agent.

Wound infection rates after biliary tract surgery can be significantly reducedb by preoperative administration of prophylactic antibacterials. Newer generation β-lactams have not proven to be of greater benefit than older agents such as cefuroxime or cefazolin. Antibacterial prophylaxis before endoscopic retrograde cholangiopancreatography (ERCP) should be reserved for patients with obstructive jaundice, since the risk of infectious complications seems to be strongly associated with this clinical condition. Failure to achieve full biliary drainage is the most important factor in predicting septicaemia, and prophylaxis should be prolonged until the bile duct is unobstructed. Piperacillin, cefazolin, cefuroxime, cefotaxime and ciprofloxacin are effective for this indication.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lea AS, Feliciano DV, Gentry LO. Intra-abdominal infections — an update. J Antimicrob Chemother 1982; 9 Suppl. A: 107–13

    Article  PubMed  Google Scholar 

  2. Csendes A, Fernandez M, Uribe P. Bacteriology of the gallbladder bile in normal subjects. Am J Surg 1975; 129: 629–31

    Article  PubMed  CAS  Google Scholar 

  3. Evidence-Based Medicine Working Group. Evidence-based medicine: a new approach to teaching the practice of medicine. JAMA 1992; 268: 2420–5

    Article  Google Scholar 

  4. Davidoff F, Haynes B, Sackett D, et al. Evidence-based medicine. BMJ 1995; 310: 1085–6

    Article  PubMed  CAS  Google Scholar 

  5. Herman RE. The spectrum of biliary stone disease. Am J Surg 1989; 158: 171–3

    Article  Google Scholar 

  6. Sievert W, Vakil NB. Emergencies of the biliary tree. Gastroenterol Clin North Am 1988; 17: 245–64

    PubMed  CAS  Google Scholar 

  7. Thompson JE, Bennion RS, Doty JE, et al. Predictive factors for bactibilia in acute cholecystitis. Arch Surg 1990; 125: 261–4

    Article  PubMed  Google Scholar 

  8. Kosowski K, Karczewska E, Kasprowicz A, et al. Bacteria in bile of patients with bile duct inflammation. Eur J Clin Microbiol 1987; 6: 575–8

    Article  PubMed  CAS  Google Scholar 

  9. Jackaman FR, Hilson GR, Marlow LS. Bile bacteria in patients with benign bile duct stricture. Br J Surg 1980; 67: 329–32

    Article  PubMed  CAS  Google Scholar 

  10. Maddocks AC, Hilson GR, Taylor R. The bacteriology of the obstructed biliary tree. Ann R Coll Surg Engl 1973; 52: 316–9

    PubMed  CAS  Google Scholar 

  11. Lygidakis NJ. Incidence of bile infection in patients with chole-docholithiasis. Am J Gastroenterol 1982; 77: 12–7

    PubMed  CAS  Google Scholar 

  12. Maluenda F, Csendes A, Burdiles P, et al. Bacteriological study of choledochal bile in patients with common bile duct stones, with or without acute suppurative cholangitis. Hepatogastro-enterol 1989; 36: 132–5

    CAS  Google Scholar 

  13. Brook I. Aerobic and anaerobic microbiology of biliary tract disease. J Clin Microbiol 1989; 27: 2373–5

    PubMed  CAS  Google Scholar 

  14. Lykkegaard-Nielsen M, Justesen T. Anaerobic and aerobic bacteriological studies in biliary tract disease. Scand J Gastroenterol 1976; 11: 437–46

    Google Scholar 

  15. England DM, Rosenblatt JE. Anaerobes in human biliary tracts. J Clin Microbiol 1977; 6: 494–8

    PubMed  CAS  Google Scholar 

  16. Leung JW, Ling TK, Chan RC, et al. Antibiotics, biliary sepsis and bile duct stones. Gastrointest Endosc 1994; 40: 716–21

    PubMed  CAS  Google Scholar 

  17. Hanau LH, Steigbigel NH. Cholangitis: pathogenesis, diagnosis, and treatment. Curr Clin Top Infect Dis 1995; 15: 153–78

    PubMed  CAS  Google Scholar 

  18. Bourgault AM, England DM, Rosenblatt JE, et al. Clinical characteristics of anaerobic bactibilia. Arch Intern Med 1979; 139: 1346–9

    Article  PubMed  CAS  Google Scholar 

  19. Shimada K, Noro T, Inamatsu T, et al. Bacteriology of acute obstructive suppurative cholangitis of the aged. J Clin Microbiol 1981; 14: 522–6

    PubMed  CAS  Google Scholar 

  20. Csendes A, Mitru N, Maluenda F, et al. Counts of bacteria and pyocites of choledocal bile in controls and in patients with gallstones or common bile duct stones with or without acute cholangitis. Hepatogastroenterology 1996; 43: 800–6

    PubMed  CAS  Google Scholar 

  21. Raper SE, Barker ME, Jones AL, et al. Anatomic correlates of bacterial cholangiovenous reflux. Surgery 1989; 105: 352–9

    PubMed  CAS  Google Scholar 

  22. Csendes A, Hurdiles P, Diaz JC, et al. Bacteriological studies of liver parenchyma in controls and in patients with gallstones or common bile duct stones with or without acute cholangitis. Hepatogastroenterology 1995; 42: 821–6

    PubMed  CAS  Google Scholar 

  23. Boey JH, Way LW. Acute cholangitis. Ann Surg 1980; 191: 264–70

    Article  PubMed  CAS  Google Scholar 

  24. Thompson JE, Tomkins RK, Longmire WP. Factors in management of acute cholangitis. Ann Surg 1982; 195: 137–45

    Article  PubMed  Google Scholar 

  25. Lau WY, Chu KW, Yuen WK, et al. Operative choledochoscopy in patients with acute cholangitis: a prospective randomised study. Br J Surg 1991; 78: 1226–9

    Article  PubMed  CAS  Google Scholar 

  26. Classen M, Safrany L. Endoscopic papillotomy and removal of gallstones. BMJ 1975; 4: 371–4

    Article  PubMed  CAS  Google Scholar 

  27. Shepherd HA, Royle G, Ross AP, et al. Endoscopic biliary endoprosthesis in the palliation of malignant obstruction of the distal common bile duct: a randomised trial. Br J Surg 1988; 75: 1166–8

    Article  PubMed  CAS  Google Scholar 

  28. Bilbao MK, Dotter CT, Lee TG, et al. Complications of endoscopic retrograde cholangiopancreatography (ERCP): a study of 10 000 cases. Gastroenterology 1976; 70: 314–20

    PubMed  CAS  Google Scholar 

  29. Deviere J, Motte S, Dumonceau JM, et al. Septicemia after endoscopic retrograde cholangiopancreatography. Endoscopy 1990; 22: 72–5

    Article  PubMed  CAS  Google Scholar 

  30. Dutta SK, Cox M, Williams RB, et al. Prospective evaluation of the risk of bacteremia and the role of antibiotics in ERCP. J Clin Gastroenterol 1989; 5: 325–9

    Article  Google Scholar 

  31. Cotton PB. Progress report - ERCP. Gut 1977; 18: 316–41

    Article  PubMed  CAS  Google Scholar 

  32. Keighley MR, Lister DM, Jacobs SI, et al. Hazards of surgical treatment due to microorganisms in the bile. Surgery 1974; 75: 578–83

    PubMed  CAS  Google Scholar 

  33. Strachan CJ, Black J, Powis SJ, et al. Prophylactic use of cephazolin against wound sepsis after cholecystectomy. BMJ 1977; 1: 1254–6

    Article  PubMed  CAS  Google Scholar 

  34. Lykkegaard-Nielsen M, Moesgaard F, Justesen T, et al. Wound sepsis after elective cholecystectomy. Scand J Gastroenterol 1981; 16: 937–40

    Article  PubMed  CAS  Google Scholar 

  35. Keighley MR, Flinn R, Alexander-Williams J. Multivariate analysis of clinical and operative finding associated with biliary sepsis. Br J Surg 1976; 63: 528–31

    Article  PubMed  CAS  Google Scholar 

  36. Meijer WS, Schmitz PI, Jeekel J. Meta-analysis of randomized controlled clinical trials of antibiotic prophylaxis in biliary tract surgery. Br J Surg 1990; 77: 283–90

    Article  PubMed  CAS  Google Scholar 

  37. Kobayashi A, Utsunomiya T, Ohbe Y, et al. Ascending cholangitis after successful surgical repair of biliary atresia. Arch Dis Child 1973; 48: 697–701

    Article  PubMed  CAS  Google Scholar 

  38. Ohi R, Hanamatsu M, Mochizuki J, et al. Progress in the treatment of biliary atresia. World J Surg 1985; 9: 285–93

    Article  PubMed  CAS  Google Scholar 

  39. Rothenberg SS, Schröter GP, Karrer FM, et al. Cholangitis after the Kasai operation for biliary atresia. J Pediatr Surg 1989; 24: 729–32

    Article  PubMed  CAS  Google Scholar 

  40. Van den Hazel SJ, Speelman P, Tytgat GN, et al. Successful treatment of recurrent cholangitis with antibiotic maintenance therapy. Eur J Clin Microbiol Infect Dis 1994; 13: 662–5

    Article  PubMed  Google Scholar 

  41. Goldman LD, Steer ML, Silen W Recurrent cholangitis after biliary surgery. Am J Surg 1983; 145: 450–4

    Article  PubMed  CAS  Google Scholar 

  42. Leblanc A, Lambert-Zechowsky N, Binge E, et al. Bacteriological analysis of jejunostomy fluid after surgery for extrahepatic biliary atresia. J Pediatr Gastroenterol Nutr 1983; 2: 307–10

    PubMed  CAS  Google Scholar 

  43. Brogard JM, Kopferschmitt J, Arnaud JP, et al. Biliary elimination of mezlocillin: an experimental and clinical study. Antimicrob Agents Chemother 1980; 18: 69–76

    Article  PubMed  CAS  Google Scholar 

  44. Gerecht WB, Henry NK, Hoffman WW, et al. Prospective randomized comparison of mezlocillin therapy alone with combined ampicillin and gentamicin therapy for patients with cholangitis. Arch Intern Med 1989; 149: 1279–84

    Article  PubMed  CAS  Google Scholar 

  45. Van Delden OM, Jan Leeuwn DJ, Jansen PL, et al. Biliary excretion of ceftriaxone into non stagnant and stagnant bile. J Antimicrob Chemother 1994; 33: 193–4

    Article  PubMed  Google Scholar 

  46. Stewart JS, Roy A, Shrivastava RK, et al. Norfloxacin levels in human bile, serum, and tissues. Rev Infect Dis 1988; 10 Suppl. 1: S125–6

    Article  Google Scholar 

  47. Leung JW, Chan RC, Cheung SW, et al. The effect of obstruction on the biliary excretion of cefoperazone and ceftazidime. J Antimicrob Chemother 1990; 25: 399–406

    Article  PubMed  CAS  Google Scholar 

  48. Van den Hazel SJ, DeVries XH, Speelman P, et al. Biliary excretion of ciprofloxacin and piperacillin in the obstructed biliary tract. Antimicrob Agents Chemother 1996; 40: 2658–60

    PubMed  Google Scholar 

  49. Thomas M. Antibiotics in bile. J Antimicrob Chemother 1983; 12: 419–22

    Article  PubMed  CAS  Google Scholar 

  50. Bergan T. Pharmacokinetic parameters and characteristics relevant to antimicrobial surgical prophylaxis. Scand J Infect Dis Suppl 1990; 70: 31–5

    PubMed  CAS  Google Scholar 

  51. Keighley MR, Drysdale RB, Quoraishi AH, et al. Antibiotics in biliary disease: the relative importance of antibiotic concentrations in the bile and serum. Gut 1976; 17: 495–500

    Article  PubMed  CAS  Google Scholar 

  52. Munro R, Sorrell TC. Biliary sepsis: reviewing treatment options. Pract Ther 1986; 31: 449–54

    CAS  Google Scholar 

  53. Thompson J, Bennion RS, Pitt HA. An analysis of infectious failures in acute cholangitis. HPB Surg 1994; 8: 139–45

    Article  PubMed  CAS  Google Scholar 

  54. Desai TK, Tsan TK. Aminoglycoside nephrotoxicity in obstructive jaundice. Am J Med 1988; 85: 47–50

    Article  PubMed  CAS  Google Scholar 

  55. Eliopoulos GM, Moellering RC. Azlocillin, mezlocillin, and piperacillin: new broad spectrum penicillins. Ann Intern Med 1982; 97: 755–60

    PubMed  CAS  Google Scholar 

  56. Müller LE, Pitt HA, Thompson JE, et al. Antibiotics in infections of the biliary tract. Surg Gynecol Obstet 1987; 165: 285–92

    PubMed  Google Scholar 

  57. Thompson JE, Pitt HA, Doty JE, et al. Broad spectrum penicillin as an adequate therapy for acute cholangitis. Surg Gynecol Obstet 1990; 171: 275–82

    PubMed  Google Scholar 

  58. Demediuk B, Speer AG, Hellyar A. Induced antibiotic resistant bacteria in cholangitis with biliary sepsis. Aust NZ J Surg 1996; 66: 778–80

    Article  CAS  Google Scholar 

  59. Wiedeman B. Selection of betalactamase producers during cephalosporin or penicillin therapy. Scand J Infect Dis 1986; 49 Suppl.: 100

    Google Scholar 

  60. Westphal JF, Brogard JM, Caro-Sampara F, et al. Assessment of the biliary excretion of piperacillin-tazobactam in humans. Antimicrob Agents Chemother 1997; 41: 1636–40

    PubMed  CAS  Google Scholar 

  61. Chamberland S, Lécuyer J, Lessard C, et al. Antibiotic susceptibility profiles of 941 gram-negative bacteria isolated from septicemic patients throughout Canada. Clin Infect Dis 1992; 15: 615–28

    Article  PubMed  CAS  Google Scholar 

  62. Bergeron MG, Mendelson J, Harding GK, et al. Cefoperazone compared with ampicillin plus tobramycin for severe biliary tract infections. Antimicrob Agents Chemother 1988; 32: 1231–6

    Article  PubMed  CAS  Google Scholar 

  63. Westphal JF, Blicklé JF, Brogard JM. Management of biliary tract infections: potential role of the quinolones. J Antimicrob Chemother 1991; 28: 486–90

    Article  PubMed  CAS  Google Scholar 

  64. Chrysanthopoulos CJ, Skoutelis AT, Starakis JC, et al. Use of ciprofloxacin in biliary sepsis. Infection 1988; 16: 249

    Article  PubMed  CAS  Google Scholar 

  65. Karachalios GN, Zografos G, Patrikakos V, et al. Biliary tract infections treated with ciprofloxacin. Infection 1993; 21: 262–4

    Article  PubMed  CAS  Google Scholar 

  66. Brogard JM, Jehl F, Paris-Bockel D, et al. Biliary elimination of ceftazidime. J Antimicrob Agents Chemother 1987; 19: 671–8

    Article  CAS  Google Scholar 

  67. Sung JJ, Lyon DJ, Suen R, et al. Intravenous ciprofloxacin as treatment for patients with acute suppurative cholangitis: a randomized, controlled clinical trial. J Antimicrob Chemother 1995; 35: 855–64

    Article  PubMed  CAS  Google Scholar 

  68. Neu HC. Bacterial resistance to fluoroquinolones. Rev Infect Dis 1988; 10 Suppl. 1: S57–63

    Article  PubMed  CAS  Google Scholar 

  69. Neu HC. Synergy of fluoroquinolones with other antimicrobial agents. Rev Infect Dis 1989; 11 Suppl. 5: S1025–35

    Article  PubMed  CAS  Google Scholar 

  70. Dooley JS, Hamilton-Miller JM, Brumfitt W, et al. Antibiotics in the treatment of biliary infection. Gut 1984; 25: 988–98

    Article  PubMed  CAS  Google Scholar 

  71. Leung JW, Cotton PB. Endoscopie nasobiliary catheter drainage in biliary and pancreatic disease. Am J Gastroenterol 1991; 86: 389–94

    PubMed  CAS  Google Scholar 

  72. Leung JW, Chung SC, Sung JY, et al. Urgent endoscopie drainage of acute suppurative cholangitis. Lancet 1989; I: 307–9

    Google Scholar 

  73. Leese T, Neoptolemos JP, Baker AR, et al. Management of acute cholangitis and the impact of endoscopie sphincterotomy. Br J Surg 1986; 73: 988–92

    Article  PubMed  CAS  Google Scholar 

  74. Leung JW, Venezuela RR. Cholangiosepsis: endoscopic drainage and antibiotic therapy. Endoscopy 1991; 23: 220–3

    Article  PubMed  CAS  Google Scholar 

  75. Chaudhary S, Turner RB. Trimethoprim-sulfamethoxazole for cholangitis following portoenterostomy for biliary atresia. J Pediatr 1981; 99: 656–8

    Article  PubMed  CAS  Google Scholar 

  76. Lonka L, Pedersen RS. Ciprofloxacin for cholangitis [letter]. Lancet 1987: II: 212

    Article  Google Scholar 

  77. Houwen RH, Bijleveld CM, deVries-Hospers HG. Ciprofloxacin for cholangitis after hepatic portoenterostomy [letter]. Lancet 1987; I: 1367

    Article  Google Scholar 

  78. Rieder I. Excretion of sulfamethoxazole and trimethoprim into human bile. I Infect Dig 1973; 128 Suppl.: S574

    Article  CAS  Google Scholar 

  79. Harding GK, Buckwold FJ, Marrie TJ, et al. Prophylaxis of recurrent urinary tract infection in female patients: efficacy of low-dose, thrice weekly therapy with trimethoprim-sulfamethoxazole. IAMA 1979; 242: 1975–7

    CAS  Google Scholar 

  80. Samonis G, Gikas A, Tolandis P, et al. Prospective study of the impact of broad-spectrum antibiotics on the yeast flora of the human gut. Eur I Clin Microbiol Infect Dis 1994; 13: 665–7

    Article  CAS  Google Scholar 

  81. Carratala I, Fernandez-Sevilla A, Tubau F, et al. Emergence of fluoroquinolone-resistant E. coli in fecal flora of cancer patients receiving norfloxacin prophylaxis. Antimicrob Agents Chemother 1996; 40: 503–5

    PubMed  CAS  Google Scholar 

  82. Brogard JM, Pinget M, Arnaud JP, et al. Biliary excretion of cefuroxime: experimental and human study. Chemotherapy 1981; 27: 18–28

    Article  PubMed  CAS  Google Scholar 

  83. Brogard JM, Jehl F, Paris-Bockel D, et al. La ceftriaxone, céphalosporine à forte élimination hépatique. Schweiz Med Wochenschr 1987; 117: 1549–59

    PubMed  CAS  Google Scholar 

  84. DeLalla F, Peruzzo L, Ferraris P, et al. Chemoprophylaxis in elective biliary tract surgery: oral norfloxacin vs intravenous piperacillin. Rev Infect Dis 1988; 10 Suppl. 1: S126–7

    Google Scholar 

  85. Kujath P. Brief report: antibiotic prophylaxis in biliary tract surgery. Am J Med 1989; 87 Suppl. 5A: 255S–7S

    Article  PubMed  CAS  Google Scholar 

  86. McArdle CS, Morran CT, Pettit L, et al. The value of oral antibiotic prophylaxis in biliary tract surgery. J Hosp Infect 1991; 19 Suppl. C: 59–64

    Article  PubMed  Google Scholar 

  87. Brandes JW, Scheffer B, Lorenz-Meyer H, et al. ERCP: complications and prophylaxis. A controlled study. Endoscopy 1981; 13: 27–30

    CAS  Google Scholar 

  88. Sauter G, Grabein B, Huber G, et al. Antibiotic prophylaxis of infectious complications with endoscopic retrograde cholangiopancreatography: a randomized controlled study. Endoscopy 1990; 22: 164–7

    Article  PubMed  CAS  Google Scholar 

  89. Finkelstein R, Yassin K, Suissa A, et al. Failure of cefonicid prophylaxis for infectious complications related to endoscopic retrograde cholangiopancreatography. Clin Infect Dis 1996; 23: 378–9

    Article  PubMed  CAS  Google Scholar 

  90. Van den Hazel SJ, Speelman P, Dankert J, et al. Piperacillin to prevent cholangitis after endoscopic retrograde cholangiopancreatography: a randomized controlled trial. Ann Intern Med 1996; 125: 442–7

    PubMed  Google Scholar 

  91. Lai EC, Lo CM, Choi TK, et al. Urgent biliary decompression after endoscopic retrograde cholangiopancreatography. Am J Surg 1989; 157: 121–5

    Article  PubMed  CAS  Google Scholar 

  92. Khardori N, Wong E, Carrasco CH, et al. Infections associated with biliary drainage procedures in patients with cancer. Rev Infect Dis 1991; 13: 587–91

    Article  PubMed  CAS  Google Scholar 

  93. Motte S, Deviere J, Dumonceau JM, et al. Risk factors for septicemia following endoscopic biliary stenting. Gastroenterology 1991; 101: 1374–81

    PubMed  CAS  Google Scholar 

  94. Niederau C, Pohlman U, Lubke H, et al. Prophylactic antibiotic treatment in therapeutic or complicated diagnostic ERCP: results of a randomized controlled clinical study. Gastrointest Endosc 1994; 40: 533–7

    Article  PubMed  CAS  Google Scholar 

  95. Byl B, Deviere J, Struelens MJ, et al. Antibiotic prophylaxis for infectious complications after therapeutic endoscopic retrograde cholangiopancreatography: a randomized, double-blind, placebo-controlled study. Clin Infect Dis 1995; 20: 1236–40

    Article  PubMed  CAS  Google Scholar 

  96. Alveyn CG, Robertson DA, Whright R, et al. Prevention of sepsis following endoscopic retrograde cholangiopancreatography. J Hosp Infect 1991; 19 Suppl. C: 65–70

    Article  PubMed  Google Scholar 

  97. Mehal WZ, Culshaw KD, Tillotson GS, et al. Antibiotic prophylaxis for ERCP: a randomized clinical trial comparing ciprofloxacin and cefuroxime in 200 patients at risk of cholangitis. Eur J Gastroenterol Hepatol 1995; 7: 841–5

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Medical B Clinic, University Hospital of Strasbourg, Strasbourg, France

    Jean-Frédéric Westphal &  Jean-Marie Brogard

Authors
  1. Jean-Frédéric Westphal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jean-Marie Brogard
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jean-Marie Brogard.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Westphal, JF., Brogard, JM. Biliary Tract Infections. Drugs 57, 81–91 (1999). https://doi.org/10.2165/00003495-199957010-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199957010-00007

Keywords

Search

Navigation